<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Cortez NE</submitter><funding>HHS | NIH | National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>USDA | National Institute of Food and Agriculture</funding><pagination>951-965</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9648418</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2(9)</volume><pubmed_abstract>Pancreatic ductal adenocarcinoma (PDAC) continues to be a major health problem. A ketogenic diet (KD), characterized by a very low carbohydrate and high fat composition, has gained attention for its anti-tumor potential. We evaluated the effect and mechanisms of feeding a strict KD alone or in combination with gemcitabine in the autochthonous LSL-Kras&lt;sup>G12D/+&lt;/sup>; LSL-Trp53 &lt;sup>R172H/+&lt;/sup>; Pdx1-Cre (KPC) mouse model. For this purpose, both male and female pancreatic tumor-bearing KPC mice were allocated to a control diet (CD; %kcal: 70% carb, 14% protein, 16% fat), a KD (%kcal: 14% protein, 1% carb, 85% fat), a CD + gemcitabine (CG), or a KD + gemcitabine (KG) group. Mice fed a KD alone or in combination with gemcitabine showed significantly increased blood β-hydroxybutyrate level</pubmed_abstract><journal>Cancer research communications</journal><pubmed_title>A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice.</pubmed_title><pmcid>PMC9648418</pmcid><funding_grant_id>CA-D-NTR-2397-H</funding_grant_id><funding_grant_id>P30CA093373</funding_grant_id><funding_grant_id>P30 CA093373</funding_grant_id><pubmed_authors>Muller M</pubmed_authors><pubmed_authors>Hwang CI</pubmed_authors><pubmed_authors>Pontifex MG</pubmed_authors><pubmed_authors>Wang F</pubmed_authors><pubmed_authors>Vauzour D</pubmed_authors><pubmed_authors>Rodriguez Lanzi C</pubmed_authors><pubmed_authors>Xu J</pubmed_authors><pubmed_authors>Mackenzie GG</pubmed_authors><pubmed_authors>Matsukuma K</pubmed_authors><pubmed_authors>Hong BV</pubmed_authors><pubmed_authors>Chen S</pubmed_authors><pubmed_authors>Vahmani P</pubmed_authors><pubmed_authors>Cortez NE</pubmed_authors><pubmed_authors>Ramsey JJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice.</name><description>Pancreatic ductal adenocarcinoma (PDAC) continues to be a major health problem. A ketogenic diet (KD), characterized by a very low carbohydrate and high fat composition, has gained attention for its anti-tumor potential. We evaluated the effect and mechanisms of feeding a strict KD alone or in combination with gemcitabine in the autochthonous LSL-Kras&lt;sup>G12D/+&lt;/sup>; LSL-Trp53 &lt;sup>R172H/+&lt;/sup>; Pdx1-Cre (KPC) mouse model. For this purpose, both male and female pancreatic tumor-bearing KPC mice were allocated to a control diet (CD; %kcal: 70% carb, 14% protein, 16% fat), a KD (%kcal: 14% protein, 1% carb, 85% fat), a CD + gemcitabine (CG), or a KD + gemcitabine (KG) group. Mice fed a KD alone or in combination with gemcitabine showed significantly increased blood β-hydroxybutyrate level</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2026-05-10T06:13:12.021Z</modification><creation>2025-04-19T12:10:45.177Z</creation></dates><accession>S-EPMC9648418</accession><cross_references><pubmed>36382086</pubmed><doi>10.1158/2767-9764.crc-22-0256</doi></cross_references></HashMap>